简易呼吸困难量表可预测慢性间质性肺疾病结局
结果显示,MRCDS纵向升高可预测慢性ILD患者不良结局,基线MRCDS在IPF中是死亡的强预测因子。
要点
- MRCDS纵向升高可预测慢性ILD患者18个月临床进展与死亡。
- 基线MRCDS是IPF患者死亡的强预测因子。
- 非IPF ILD中仅MRCDS纵向变化有预测价值。
核心结论
- MRCDS纵向升高能较准确预测慢性ILD患者的不良结局。
- 基线MRCDS仍是IPF患者死亡的强预测因子。
- MRCDS应纳入慢性ILD临床病程的整体评估。
研究设计与样本
- 评估基线(诊断时)及3-6个月MRCDS变化。
- 终点为18个月临床进展和18个月生存。
主要发现
- 观察期末54例(47%)出现临床进展,包括22例死亡和3例肺移植。
- IPF患者中,MRCDS纵向升高预测临床进展的AUC=0.76,敏感性62%,特异性91%。
- IPF患者中,基线MRCDS预测死亡的AUC=0.80,敏感性87%,特异性57%。
- 非IPF ILD患者中,MRCDS纵向升高预测临床进展的AUC=0.81,敏感性85%,特异性77%。
- 非IPF ILD患者中,MRCDS纵向升高预测死亡的AUC=0.76,敏感性91%,特异性61%。
关键数值与推荐
- 临床进展定义:FVC占预计值百分比绝对下降≥10%,或6分钟步行距离下降≥50 m,或因呼吸原因住院、肺移植评估或死亡。
临床怎么用
- 可将MRCDS作为慢性ILD患者随访中评估临床病程的简易工具。
- 对IPF患者应关注基线MRCDS以辅助死亡风险评估。
- 对非IPF ILD患者应动态监测MRCDS变化以预测进展和死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The Medical Research Council dyspnoea score (MRCDS) is a simple, objective scale to assess dyspnoea, the main complaint in patients with chronic interstitial lung disease (ILD). We sought to investigate whether MRCDS is a predictor of outcome in patients with chronic ILD. METHODS: One hundred and fifteen patients (50 idiopathic pulmonary fibrosis (IPF) and 65 non-IPF ILD) were retrospectively studied. Baseline (time of diagnosis) MRCDS and 3-6-month changes were considered. Endpoints were (i) 18-month clinical progression, defined as either: ≥10% absolute reduction in forced vital capacity (FVC) percent predicted; ≥50-m decline in 6-min walk distance; hospitalization for respiratory causes; lung transplantation (LTx) assessment or death and (ii) 18-month survival. RESULTS: At the end of the observation period, 54 subjects (47%) experienced clinical progression (including 22 deaths and 3 LTx). In patients with IPF, a longitudinal increase in MRCDS predicted clinical progression significantly (area under the curve (AUC) = 0.76, sensitivity = 62%, specificity = 91%); baseline MRCDS was a strong predictor of mortality (AUC = 0.80, sensitivity = 87%, specificity = 57%). In patients with non-IPF ILD, longitudinal increases in MRCDS, but not baseline values, were predictive of both clinical progression (AUC = 0.81, sensitivity = 85%, specificity = 77%) and mortality (AUC = 0.76, sensitivity = 91%, specificity = 61%). Considering the whole population, MRCDS increase and FVC decline were independent predictors of mortality. CONCLUSION: Longitudinal increases of MRCDS predict poor outcome in chronic ILD, with good accuracy. Baseline MRCDS remains a strong predictor of mortality in IPF. MRCDS should be included in the global assessment of the clinical course of chronic ILD.
引用
- Khadawardi H, Mura M. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease. Respirology. 2016. PMID: 27862639. doi:10.1111/resp.12945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。